National Institute for Health and Clinical Excellence (NICE)
Court warns CCG over disagreeing with NICE guidance
Clinical Commissioning Groups (CCGs) cannot choose not to follow NICE guidance because they merely disagree with it, even where there is no statutory duty to do so, a court has ruled.
This follows the case of Elizabeth Rose, a 25 year old woman who has suffered from a severe form of Crohn's disease since she was 14. Her condition had deteriorated and her doctors recommended bone marrow transplantation and chemotherapy to hopefully bring the disease into remission. This treatment can, however, lead to infertility and the early onset of the menopause.
The claimant wished to secure the best chance of having her own genetic children, and sought NHS funding for oocyte cryopreservation before beginning chemotherapy.
In February 2013, NICE updated its clinical guideline on fertility which gave stronger support for the effectiveness of oocyte cryopreservation. NICE recommends that oocyte or embryo cryopreservation is offered as appropriate to women of reproductive age who are preparing for medical treatment for cancer that is likely to make them infertile.
Clinicians at King's College Hospital Foundation Trust applied for funding for Ms Rose's treatment but Thanet CCG denied the treatment in May 2013 on the grounds that there was not enough evidence to demonstrate its effectiveness. The cost of the Procedure is £4,050.
The CCG's policy was not to grant funding for the procedure unless the applicant has any exceptional clinical circumstances. The CCG considered that the claimant's circumstances were broadly in line with the group of similar patients addressed by the policy and that no exceptionality had been established. Consequently, the CCG refused funding in June 2013.
The NICE fertility guidance was not in the form of a technology appraisal or specialised technology appraisal which CCGs must legally comply with and provide funding for within three months of publication. Instead, the recommendations were made as part of a clinical guideline, and so CCGs do not have a legal duty to comply with NICE guidelines.
Despite this, the court ruled that the CCG was under an obligation in public law to have regard for the NICE guidance and to provide clear reasons for any general policy that does not follow NICE guidance.
The issue in this case was whether CCGs may legitimately disagree with NICE on matters concerning the current state of medical science. It was NICE's view that the evidence base supported the effectiveness of the procedure, and the CCG's sole basis for not following NICE's recommendation was that it disagreed.
Previous case law from 1997 (R v North Derbyshire Health Authority, ex parte Fisher) had found that a decision not to follow national policy in the form of guidance from the Secretary of State was only lawful if there was some 'special factor' which 'exceptionally justified departure'. Disagreement with the policy was not enough. The court applied this judgment to the present case and found that no basis or reasoning on grounds of exceptionality was put forward by the CCG.
The judge, Justice Jay, pointed out that the CCG could have found other reasons, on the basis of exceptionality, for not following the guidance. It had not done so and mere disagreement was insufficient. The policy was therefore unlawful.
Thanet CCG has said that they will consider the full written judgement carefully and will work closely with NHS England in doing so. If necessary they will review their policy on the freezing of eggs.
Andrew Dillon, Chief Executive of NICE, said: “This court ruling
highlights that CCGs cannot simply ignore NICE guidelines without having a
clear clinical case for doing so. NICE guidelines are based on the best
available evidence. Our fertility guideline was recently updated and provides
clear support for the use of oocyte cryopreservation.”
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Children and young people need accurate, accessible information about their healthcare05/03/2021 11:25:00
New draft guidance from NICE published today recommends ensuring children and young people are fully informed about their health so that they are empowered to take an active role in their healthcare
Register now for the HTAi 2021 Virtual Annual Meeting05/03/2021 11:15:00
The Health Technology Assessment International (HTAi) 2021 Annual Meeting will be held virtually from 19-23 June 2021, and registration is now open.
Thousands of breast cancer patients to have routine access to NICE-approved drug combination01/03/2021 15:28:15
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).
Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver cancer26/02/2021 16:15:00
Hundreds of people with advanced liver cancer (also called hepatocellular carcinoma or HCC) are set to benefit after NICE today (26 February 2021) published final draft guidance recommending a cancer treatment called selective internal radiation therapy (SIRT) as an option for treating the condition.
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE25/02/2021 15:20:00
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria25/02/2021 14:15:00
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
A new instrument for consideration of a broader range of benefits for people, their families and carers18/02/2021 14:15:00
Blog posted by: Bhash Naidoo Senior Technical Adviser – Health Economics at NICE, 17 February 2021.
Skin cancer drug recommended for routine NHS use15/02/2021 09:15:00
An appeal period has now opened until 26 February 2021.
NICE recommends treatment options for severe pregnancy sickness in new draft guidance11/02/2021 15:15:00
Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptoms, with most conditions improving or stopping completely by around 16 to 20 weeks